相关实验视频
Updated: Mar 16, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.6K
在皮肤免疫媒介炎症疾病中使用JAK抑制剂的现实安全性:来自多国队列研究的盒装警告结果
Teng-Li Lin1,2, Yi-Hsuan Fan3, Kuo-Sheng Fan4
1Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
Clinical pharmacology and therapeutics
|March 14, 2026
概括
简氏激酶抑制剂 (JAKis) 在皮肤免疫介导炎症性疾病 (IMIDs) 中显示出更好的安全性. 与传统疗法相比,JAKis在两年内没有增加死亡,MACE,VTE或恶性瘤的风险.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 简氏激酶抑制剂 (JAKis) 对皮肤免疫介导炎症性疾病 (IMID) 有效.
- 由于从类风湿性关节炎试验中提醒的盒子警告存在安全问题,造成皮肤IMID的不确定性.
- 需要实际的安全数据来比较JAKis与皮肤IMID中的常规免疫调节剂 (cIMs).
研究的目的:
- 在皮肤IMID患者中比较JAKis与cIMs的真实安全性.
- 评估死亡率,主要不良心血管事件 (MACE),静脉血栓栓塞 (VTE) 和恶性瘤的风险.
主要方法:
- 使用TriNetX数据库进行的跨国回顾性队列研究.
- 17,068名12岁以上的患者患有牛皮病,亚托皮性皮肤炎或空白脱发症.
- 在两年的时间里,JAKis (托法西提尼布,阿巴达西提尼布,德乌克拉维西提尼布,巴里西提尼布,阿布罗西提尼布,里特利西提尼布) 与cIMs (甲基,环素) 的倾向性得分匹配比较.
主要成果:
- 与cIM队列相比,JAKi队列的全因死亡率 (0.28%vs. 0.62%) 和MACE (1.15%vs. 1.95%) 的发病率较低.
- 与JAKis.一起观察到死亡率 (HR 0.47) 和MACE (HR 0.63) 的降低风险.
- 没有增加风险的VTE (HR 0.80) 或恶性瘤 (HR 0.85) 与JAKis;子组分析证实了安全性.
结论:
- 在两年时间里,JAKis在皮肤IMID中表现出与cIM相比的可比或更好的安全性.
- 在这个患者群体中,JAKs与死亡率,MACE,VTE或恶性瘤的风险增加无关.
- 这些发现支持JAKis在皮肤IMID中的使用,解决了先前的安全问题.
相关概念视频
The JAK-STAT Signaling Pathway
13.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.6K
Skin Cancer
6.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.5K
Immunodeficiency Diseases
2.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
2.7K
Skin Diseases and Disorders
6.0K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
6.0K
Hypersensitivity Reactions: Cytolytic Reactions
87
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
87
Hypersensitivity Reactions: Immune-Complex Reactions
86
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
86

